| Literature DB >> 31244218 |
Michael P Luciano1, Jung-Man Namgoong2,3, Roger R Nani1, So-Hyun Nam2,4, Choonghee Lee5, Il Hyung Shin5, Martin J Schnermann1, Jaepyeong Cha1,6.
Abstract
Despite advances, visual inspection, palpation, and intraoperative ultrasound remain the most utilized tools during surgery today. A particularly challenging issue is the identification of the biliary system due to its complex architecture partially embedded within the liver. Fluorescence guided surgical interventions, particularly using near-infrared (NIR) wavelengths, are an emerging approach for the real-time assessment of the hepatobiliary system. However, existing fluorophores, such as the FDA-approved indocyanine green (ICG), have significant limitations for rapid and selective visualization of bile duct anatomy. Here we report a novel NIR fluorophore, BL (Bile Label)-760, which is exclusively metabolized by the liver providing high signal in the biliary system shortly after intravenous administration. This molecule was identified by first screening a small set of known heptamethine cyanines including clinically utilized agents. After finding that none of these were well-suited, we then designed and tested a small series of novel dyes within a prescribed polarity range. We validated the molecule that emerged from these efforts, BL-760, through animal studies using both rodent and swine models employing a clinically applicable imaging system. In contrast to ICG, BL-760 fluorescence revealed a high target-to-background ratio (TBR) of the cystic duct relative to liver parenchyma 5 min after intravenous injection. During hepatic resection surgery, intrahepatic ducts were clearly highlighted, and bile leakage was easily detected. In conclusion, BL-760 has highly promising properties for intraoperative navigation during hepatobiliary surgery.Entities:
Keywords: bile duct; fluorescence laparoscopy; hepatobiliary surgery; heptamethine cyanine; near-infrared fluorescence
Mesh:
Substances:
Year: 2019 PMID: 31244218 PMCID: PMC8274942 DOI: 10.1021/acs.molpharmaceut.9b00453
Source DB: PubMed Journal: Mol Pharm ISSN: 1543-8384 Impact factor: 4.939